<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00628290</url>
  </required_header>
  <id_info>
    <org_study_id>CBD-CT1</org_study_id>
    <secondary_id>SMRI Grant ID: 00-093</secondary_id>
    <nct_id>NCT00628290</nct_id>
  </id_info>
  <brief_title>Evaluation of the Antipsychotic Efficacy of Cannabidiol in Acute Schizophrenic Psychosis</brief_title>
  <acronym>CBD-CT1</acronym>
  <official_title>Evaluation of the Antipsychotic Efficacy of the Phytocannabinoid Cannabidiol in Treating Acute Schizophrenic Psychosis. A Double-Blind, Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cologne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cologne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A controlled, randomized study on the treatment of schizophrenic psychosis with cannabidiol,&#xD;
      a phytocannabinoid is performed. This approach is based upon recent findings indicating that&#xD;
      the human endogenous cannabinoid system is significantly involved in the pathogenesis of&#xD;
      schizophrenia. Our group has shown, for example, that Δ9-tetrahydrocannabinol (Δ9-THC) is&#xD;
      able to provoke schizophrenia-like psychotic symptoms in healthy volunteers. This, as well as&#xD;
      the capability of Δ9-THC to exacerbate productive psychotic symptoms in schizophrenic&#xD;
      patients, has recently been confirmed by others. Furthermore, we found that the en-dogenous&#xD;
      brain constituent anandamide, an endogenous Δ9-THC agonist, is significantly elevated in the&#xD;
      CSF of schizophrenic patients. Cannabinergic substances such as anandamide may enhance&#xD;
      dopaminergic neurotrans-mission by increasing dopamine turnover. They may also influence the&#xD;
      onset or course of schizophrenia by as yet unidentified mechanisms We seek to investigate the&#xD;
      efficacy of cannabidiol in the treatment of schizophrenic and schizophreniform psy-choses,&#xD;
      because there is evidence that CB1 antagonists such as SR141716 and cannabidiol have&#xD;
      antipsychotic effects comparable to those of classic neuroleptic drugs. Furthermore,&#xD;
      cannabidiol is well tolerated showing few side effects in humans. Cannabidiol may serve as an&#xD;
      antipsychotic medication that is not primarily based upon an antidopaminergic but upon&#xD;
      different mechanisms, especially anticannabinergic ones. It may therefore be an effec-tive&#xD;
      medication in at least a subgroup of schizophrenic and schizophreniform patients and may be&#xD;
      expected to show additional anxiolytic effects and only minor side effects.&#xD;
&#xD;
      The control condition in this parallel design will be an established neuroleptic treatment&#xD;
      with amisulpride that is primarely an antidopaminergic drug. Thus, we will study not only the&#xD;
      antipsychotic efficacy of cannabidiol, but we will also compare the effects of both treatment&#xD;
      strategies on side effects and neuropsychological functioning.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">November 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in BPRS total value.</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in PANSS scores.</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EPS</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight gain</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prolactin levels in serum</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabidiol</intervention_name>
    <description>Capsules, 3 times daily, 200 mg, 4 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amisulpride</intervention_name>
    <description>Capsules, 3 times daily, 200 mg, 4 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of schizophrenia or schizophreniform psychosis according to DSM-IV.&#xD;
&#xD;
          -  BPRS score &gt;36 and BPRS psychosis cluster &gt; 12.&#xD;
&#xD;
          -  Ability to provide written informed consent.&#xD;
&#xD;
          -  Participants are required an adequate contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any severe neurological or somatic disorder.&#xD;
&#xD;
          -  Other psychiatric disorders including addictive disorders.&#xD;
&#xD;
          -  Positive urine drug screening for any compound except benzodiazepines.&#xD;
&#xD;
          -  No pregnancy or breast feeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franz-Markus Leweke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cologne, Dept. of Psychiatry and Psychotherapy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Cologne, Dept. of Psychiatry and Psychotherapy</name>
      <address>
        <city>Cologne</city>
        <state>NRW</state>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.ecnp.net</url>
    <description>Related Info</description>
  </link>
  <verification_date>January 2008</verification_date>
  <study_first_submitted>February 26, 2008</study_first_submitted>
  <study_first_submitted_qc>February 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2008</study_first_posted>
  <last_update_submitted>March 17, 2008</last_update_submitted>
  <last_update_submitted_qc>March 17, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. F. Markus Leweke</name_title>
    <organization>University of Cologne</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cannabidiol</mesh_term>
    <mesh_term>Amisulpride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

